APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics for Severe Asthma

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biologics for Severe Asthma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025187 pages

Choose your research edition.

Industry ResearchBiologics for Severe Asthma Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics for Severe Asthma Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biologics for Severe Asthma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics for Severe Asthma Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics for Severe Asthma Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Biologics for Severe Asthma market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biologics for Severe Asthma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biologics for Severe Asthma include Teva Pharmaceuticals, Sanofi, Novartis, Roche, Regeneron Pharmaceuticals, GSK, AstraZeneca and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologics for Severe Asthma market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics for Severe Asthma and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics for Severe Asthma sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologics for Severe Asthma market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics for Severe Asthma Segment by Company

Teva Pharmaceuticals

Sanofi

Novartis

Roche

Regeneron Pharmaceuticals

GSK

AstraZeneca

Amgen

Biologics for Severe Asthma Segment by Type

Omalizumab

Benralizumab

Dupirumab

Mepolizumab

Reslizumab

Tezepelumab-ekko

Biologics for Severe Asthma Segment by Application

Clinic

Hospital

Other

Biologics for Severe Asthma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics for Severe Asthma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics for Severe Asthma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics for Severe Asthma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics for Severe Asthma market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologics for Severe Asthma manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biologics for Severe Asthma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biologics for Severe Asthma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biologics for Severe Asthma Industry Trends Table 2. Biologics for Severe Asthma Industry Drivers Table 3. Biologics for Severe Asthma Industry Opportunities and Challenges Table 4. Biologics for Severe Asthma Industry Restraints Table 5. Global Biologics for Severe Asthma Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biologics for Severe Asthma Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biologics for Severe Asthma Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Biologics for Severe Asthma Sales Market Share by Manufacturers Table 9. Global Biologics for Severe Asthma Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Biologics for Severe Asthma Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biologics for Severe Asthma Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biologics for Severe Asthma Manufacturers, Product Type & Application Table 13. Global Biologics for Severe Asthma Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologics for Severe Asthma by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Omalizumab Table 17. Major Manufacturers of Benralizumab Table 18. Major Manufacturers of Dupirumab Table 19. Major Manufacturers of Mepolizumab Table 20. Major Manufacturers of Reslizumab Table 21. Major Manufacturers of Tezepelumab-ekko Table 22. Global Biologics for Severe Asthma Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Biologics for Severe Asthma Sales by Type (2021-2026) & (K Units) Table 24. Global Biologics for Severe Asthma Sales by Type (2027-2032) & (K Units) Table 25. Global Biologics for Severe Asthma Sales Market Share by Type (2021-2026) Table 26. Global Biologics for Severe Asthma Sales Market Share by Type (2027-2032) Table 27. Global Biologics for Severe Asthma Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Biologics for Severe Asthma Revenue by Type (2021-2026) & (K Units) Table 29. Global Biologics for Severe Asthma Revenue by Type (2027-2032) & (K Units) Table 30. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2026) Table 31. Global Biologics for Severe Asthma Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Other Table 35. Global Biologics for Severe Asthma Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Biologics for Severe Asthma Sales by Application (2021-2026) & (K Units) Table 37. Global Biologics for Severe Asthma Sales by Application (2027-2032) & (K Units) Table 38. Global Biologics for Severe Asthma Sales Market Share by Application (2021-2026) Table 39. Global Biologics for Severe Asthma Sales Market Share by Application (2027-2032) Table 40. Global Biologics for Severe Asthma Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Biologics for Severe Asthma Revenue by Application (2021-2026) & (K Units) Table 42. Global Biologics for Severe Asthma Revenue by Application (2027-2032) & (K Units) Table 43. Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2026) Table 44. Global Biologics for Severe Asthma Revenue Market Share by Application (2027-2032) Table 45. Global Biologics for Severe Asthma Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Biologics for Severe Asthma Sales by Region (2021-2026) & (K Units) Table 47. Global Biologics for Severe Asthma Sales Market Share by Region (2021-2026) Table 48. Global Biologics for Severe Asthma Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Biologics for Severe Asthma Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 52. North America Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 53. Europe Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 55. Europe Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Biologics for Severe Asthma Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Biologics for Severe Asthma Sales by Country (2027-2032) & (K Units) Table 62. Global Biologics for Severe Asthma Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Biologics for Severe Asthma Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Biologics for Severe Asthma Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Biologics for Severe Asthma Revenue Market Share by Region (2021-2026) Table 66. Global Biologics for Severe Asthma Revenue Market Share by Region (2027-2032) Table 67. Teva Pharmaceuticals Company Information Table 68. Teva Pharmaceuticals Business Overview Table 69. Teva Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 71. Teva Pharmaceuticals Recent Development Table 72. Sanofi Company Information Table 73. Sanofi Business Overview Table 74. Sanofi Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Sanofi Biologics for Severe Asthma Product Portfolio Table 76. Sanofi Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Novartis Biologics for Severe Asthma Product Portfolio Table 81. Novartis Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Roche Biologics for Severe Asthma Product Portfolio Table 86. Roche Recent Development Table 87. Regeneron Pharmaceuticals Company Information Table 88. Regeneron Pharmaceuticals Business Overview Table 89. Regeneron Pharmaceuticals Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio Table 91. Regeneron Pharmaceuticals Recent Development Table 92. GSK Company Information Table 93. GSK Business Overview Table 94. GSK Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. GSK Biologics for Severe Asthma Product Portfolio Table 96. GSK Recent Development Table 97. AstraZeneca Company Information Table 98. AstraZeneca Business Overview Table 99. AstraZeneca Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. AstraZeneca Biologics for Severe Asthma Product Portfolio Table 101. AstraZeneca Recent Development Table 102. Amgen Company Information Table 103. Amgen Business Overview Table 104. Amgen Biologics for Severe Asthma Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Amgen Biologics for Severe Asthma Product Portfolio Table 106. Amgen Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. Biologics for Severe Asthma Distributors List Table 110. Biologics for Severe Asthma Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Biologics for Severe Asthma Product Image Figure 2. Global Biologics for Severe Asthma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics for Severe Asthma Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologics for Severe Asthma Sales (2021-2032) & (K Units) Figure 5. Global Biologics for Severe Asthma Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biologics for Severe Asthma Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Omalizumab Image Figure 9. Benralizumab Image Figure 10. Dupirumab Image Figure 11. Mepolizumab Image Figure 12. Reslizumab Image Figure 13. Tezepelumab-ekko Image Figure 14. Global Biologics for Severe Asthma Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Biologics for Severe Asthma Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Biologics for Severe Asthma Sales Market Share by Type (2021-2032) Figure 17. Global Biologics for Severe Asthma Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Biologics for Severe Asthma Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Other Image Figure 23. Global Biologics for Severe Asthma Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Biologics for Severe Asthma Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Biologics for Severe Asthma Sales Market Share by Application (2021-2032) Figure 26. Global Biologics for Severe Asthma Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Biologics for Severe Asthma Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2032) Figure 29. North America Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 31. U.S. Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 36. Germany Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 43. China Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Biologics for Severe Asthma Sales Market Share by Country (2021-2032) Figure 51. Brazil Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Biologics for Severe Asthma Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Biologics for Severe Asthma Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Biologics for Severe Asthma Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Biologics for Severe Asthma Revenue (2021-2032) & (US$ Million) Figure 62. North America Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Biologics for Severe Asthma Revenue (2021-2032) & (US$ Million) Figure 64. Europe Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Biologics for Severe Asthma Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Biologics for Severe Asthma Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Biologics for Severe Asthma Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Biologics for Severe Asthma Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Omalizumab
  • Benralizumab
  • Dupirumab
  • Mepolizumab
  • Reslizumab
  • Tezepelumab-ekko
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Novartis
  • Roche
  • Regeneron Pharmaceuticals
  • GSK
  • AstraZeneca
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologics for Severe Asthma Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologics for Severe Asthma Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biologics for Severe Asthma Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biologics for Severe Asthma Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biologics for Severe Asthma Market Dynamics
  1. 2.1 Biologics for Severe Asthma Industry Trends
  2. 2.2 Biologics for Severe Asthma Industry Drivers
  3. 2.3 Biologics for Severe Asthma Industry Opportunities and Challenges
  4. 2.4 Biologics for Severe Asthma Industry Restraints
3 Biologics for Severe Asthma Market by Manufacturers
  1. 3.1 Global Biologics for Severe Asthma Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biologics for Severe Asthma Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biologics for Severe Asthma Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biologics for Severe Asthma Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologics for Severe Asthma Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biologics for Severe Asthma Manufacturers, Product Type & Application
  7. 3.7 Global Biologics for Severe Asthma Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologics for Severe Asthma Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologics for Severe Asthma Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologics for Severe Asthma Tier 1, Tier 2, and Tier 3
4 Biologics for Severe Asthma Market by Type
  1. 4.1 Biologics for Severe Asthma Type Introduction
  2. 4.1.1 Omalizumab
  3. 4.1.2 Benralizumab
  4. 4.1.3 Dupirumab
  5. 4.1.4 Mepolizumab
  6. 4.1.5 Reslizumab
  7. 4.1.6 Tezepelumab-ekko
  8. 4.2 Global Biologics for Severe Asthma Sales by Type
  9. 4.2.1 Global Biologics for Severe Asthma Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Biologics for Severe Asthma Sales by Type (2021-2032)
  11. 4.2.3 Global Biologics for Severe Asthma Sales Market Share by Type (2021-2032)
  12. 4.3 Global Biologics for Severe Asthma Revenue by Type
  13. 4.3.1 Global Biologics for Severe Asthma Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Biologics for Severe Asthma Revenue by Type (2021-2032)
  15. 4.3.3 Global Biologics for Severe Asthma Revenue Market Share by Type (2021-2032)
5 Biologics for Severe Asthma Market by Application
  1. 5.1 Biologics for Severe Asthma Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Biologics for Severe Asthma Sales by Application
  6. 5.2.1 Global Biologics for Severe Asthma Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics for Severe Asthma Sales by Application (2021-2032)
  8. 5.2.3 Global Biologics for Severe Asthma Sales Market Share by Application (2021-2032)
  9. 5.3 Global Biologics for Severe Asthma Revenue by Application
  10. 5.3.1 Global Biologics for Severe Asthma Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biologics for Severe Asthma Revenue by Application (2021-2032)
  12. 5.3.3 Global Biologics for Severe Asthma Revenue Market Share by Application (2021-2032)
6 Global Biologics for Severe Asthma Sales by Region
  1. 6.1 Global Biologics for Severe Asthma Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologics for Severe Asthma Sales by Region (2021-2032)
  3. 6.2.1 Global Biologics for Severe Asthma Sales by Region (2021-2026)
  4. 6.2.2 Global Biologics for Severe Asthma Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biologics for Severe Asthma Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biologics for Severe Asthma Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biologics for Severe Asthma Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biologics for Severe Asthma Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biologics for Severe Asthma Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biologics for Severe Asthma Revenue by Region
  1. 7.1 Global Biologics for Severe Asthma Revenue by Region
  2. 7.1.1 Global Biologics for Severe Asthma Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biologics for Severe Asthma Revenue by Region (2021-2026)
  4. 7.1.3 Global Biologics for Severe Asthma Revenue by Region (2027-2032)
  5. 7.1.4 Global Biologics for Severe Asthma Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biologics for Severe Asthma Revenue (2021-2032)
  8. 7.2.2 North America Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biologics for Severe Asthma Revenue (2021-2032)
  11. 7.3.2 Europe Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biologics for Severe Asthma Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biologics for Severe Asthma Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biologics for Severe Asthma Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Biologics for Severe Asthma Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Biologics for Severe Asthma Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Biologics for Severe Asthma Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Regeneron Pharmaceuticals
  26. 8.5.1 Regeneron Pharmaceuticals Company Information
  27. 8.5.2 Regeneron Pharmaceuticals Business Overview
  28. 8.5.3 Regeneron Pharmaceuticals Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Regeneron Pharmaceuticals Biologics for Severe Asthma Product Portfolio
  30. 8.5.5 Regeneron Pharmaceuticals Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK Biologics for Severe Asthma Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Biologics for Severe Asthma Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Biologics for Severe Asthma Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Biologics for Severe Asthma Product Portfolio
  48. 8.8.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologics for Severe Asthma Value Chain Analysis
  2. 9.1.1 Biologics for Severe Asthma Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologics for Severe Asthma Production Mode & Process
  6. 9.2 Biologics for Severe Asthma Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologics for Severe Asthma Distributors
  9. 9.2.3 Biologics for Severe Asthma Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst